

Hetero Drugs signs up with Gilead

Hyderabad, September 16

Hetero Drugs has obtained licensing rights to manufacture and market Sofosbuvir and combination drug Ledipasvir/Sofosbuvir with approval from Gilead Sciences Inc, US. The Hyderabad-based company can market the drug in 90 countries. The drug is used for the treatment of chronic hepatitis C. The company is committed to bring hepatitis C medicines to India, where about 1.8 per cent of the population are affected by the problem. OUR

BUREAU

Company